Versigent (NYSE:VGNT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $54.00.
VGNT has been the subject of a number of recent analyst reports. Wells Fargo & Company lifted their target price on Versigent from $48.00 to $56.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. The Goldman Sachs Group reissued a “buy” rating and issued a $59.00 price target on shares of Versigent in a report on Wednesday, August 5th. UBS Group cut their price objective on shares of Versigent from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, July 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $54.00 price objective on shares of Versigent in a research note on Wednesday, August 5th. Finally, Fox Advisors cut shares of Versigent from an “overweight” rating to an “equal weight” rating in a report on Wednesday, August 5th.
View Our Latest Analysis on Versigent
Versigent Price Performance
Versigent (NYSE:VGNT – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.34. The company had revenue of $2.44 billion for the quarter, compared to analysts’ expectations of $2.29 billion. As a group, equities analysts anticipate that Versigent will post 7.23 EPS for the current year.
Versigent Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Friday, September 4th were given a dividend of $0.13 per share. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Friday, September 4th.
Insider Buying and Selling at Versigent
In other Versigent news, Director Kevin Clark sold 74,130 shares of Versigent stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $45.67, for a total transaction of $3,385,517.10. Following the completion of the sale, the director directly owned 124,849 shares in the company, valued at $5,701,853.83. The trade was a 37.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HBK Investments L P purchased a new stake in Versigent during the second quarter valued at about $14,439,000. Sequoia Financial Advisors LLC bought a new position in shares of Versigent during the 2nd quarter valued at about $220,000. IPG Investment Advisors LLC bought a new position in shares of Versigent during the 2nd quarter valued at about $871,000. WINTON GROUP Ltd purchased a new position in shares of Versigent during the 2nd quarter valued at about $8,397,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Versigent during the 2nd quarter valued at about $418,000.
About Versigent
Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.
Featured Stories
- Five stocks we like better than Versigent
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
